Health Technology Assessment: Evaluation of 7 Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
DOI: https://doi.org/10.2147/rmhp.s455897
2024-04-24
Risk Management and Healthcare Policy
Abstract:Zeyu Xie, Jia Hu, Mengting Li, Xiao Hu, Jisheng Chen Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People's Republic of China Correspondence: Jisheng Chen, Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, 510080, People's Republic of China, Tel +86 20-87622305, Fax +86 20-61321967, Email Purpose: This study provides a reference for healthcare organizations in the selection and rational use of glucagon-like peptide-1 receptor agonists (GLP-1RAs), based on the Rapid Guide for Drug Evaluation and Selection in Chinese Medical Institutions (Second Edition). Methods: According to the Rapid Guide for Drug Evaluation and Selection in Chinese Medical Institutions (Second Edition) released in 2023, relevant databases such as PubMed, Cochrane, and Embase, drug labels, and clinical guidelines were searched for drug information. We systematically evaluated 7 GLP-1RAs marketed in China for safety, efficacy, economy, pharmacological properties, and other attributes using a percentage scoring method. Results: The final assessment result scores from highest to lowest were semaglutide (71.5 points), dulaglutide (68.9 points), liraglutide (68.7 points), exenatide (62.5 points), lixisenatide (59.9 points), polyethylene glycol loxenatide (55.9 points), and benaglutide (45.1 points). Conclusion: When a healthcare organization introduces GLP-1RAs to their hospital, they can refer to the assessment results and use the top three recommended medications: semaglutide, dulaglutide, and liraglutide. Keywords: glucagon-like peptide-1 receptor agonist, health technology assessment, type 2 diabetes mellitus, drug evaluation Hospital-based health technology assessment (HB-HTA) refers to the comprehensive and systematic evaluation of relevant health technologies based on the actual needs of hospitals, using the principles and methods of evidence-based medicine and health technology assessment to make rapid decisions about the selection, acquisition, and use of new technologies to improve health equity and is a commonly used policy analysis tool internationally. 1,2 The incidence of diabetes is increasing due to changes in diet and lifestyle. Type 2 diabetes mellitus (T2DM) accounts for approximately 98% of diabetes diagnoses globally, although the exact proportion varies greatly from country to country. 3 It is estimated that 530 million adults worldwide have diabetes, with a global prevalence of 10.5% among adults aged 20–79 years. 4,5 The prevalence of diabetes among adults aged 20–79 years in China increased by 71.1%, from 4.7% in 1990 to 8.0% in 2019. Furthermore, the prevalence of diabetes among adults aged 20–79 in China is projected to increase from 8.2% to 9.7% in 2020–2030 compared with 2019. These statistics highlight the severity of the T2DM epidemic in China. According to a 2016 report, over 1.9 billion adults aged 18 or older were overweight worldwide, with more than 650 million being obese. The report also found that 39% of adults aged 18 or older were overweight and 13% were obese. 6 Overweight and obesity are significant risk factors for developing T2DM. 7 Patients with T2DM are frequently overweight or obese, and obesity exacerbates the risk of cardiovascular disease in these patients. Weight reduction can help delay the progression of prediabetes to T2DM. Furthermore, Diabetes is a risk factor for cardiovascular disease, which is the leading cause of death in patients with diabetes. 8 Patients with diabetes have a 2–4 times higher risk of cardiovascular disease compared to those without diabetes. 9 Most patients diagnosed with T2DM are between 50 and 60 years old and are at a high risk for atherosclerotic cardiovascular disease (ASCVD) if they are aged 40 or older. GLP-1RAs is currently widely used in clinical practice due to its significant benefits. It has been shown to reduce body weight, reduce the risk of ASCVD, and improve atherosclerosis and lipids, in addition to its significant glucose-lowering effects. The 2023 American Diabetes Association guidelines recommend GLP-1RAs or sodium-glucose cotransporter-2 inhibitors (SGLT-2i) with cardiovascular benefits as one of the indispensable medications for the treatment of T2DM, along with significant weight loss, in addition to metformin therapy. 10 There are several drugs available for treating T2DM, including 7 GLP-1RAs injections that have been marketed in China to date. Additionally, an oral form of GLP-1RAs, as well as a GIP and GLP-1 dual agonist (tirzepatide), will also be marketed in China. This may pose challenges for healthcare organizations screening GLP-1RAs f -Abstract Truncated-
health care sciences & services,health policy & services